Literature DB >> 28848841

The COPD Pipeline XXVII.

Nicholas Gross1.   

Abstract

Keywords:  AQX-1125; FDA overhaul; VX661; ivacaftor; lumacaftor; new clinical trials; p38 MAPK inhibitors; reporting trial results

Year:  2015        PMID： 28848841      PMCID： PMC5556971          DOI： 10.15326/jcopdf.2.2.2015.0137

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN： 2372-952X


× No keyword cloud information.
  5 in total

1.  The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma.

Authors:  B R Leaker; P J Barnes; B J O'Connor; F Y Ali; P Tam; J Neville; L F Mackenzie; T MacRury
Journal:  Clin Exp Allergy       Date:  2014-09       Impact factor: 5.018

2.  Compliance with results reporting at ClinicalTrials.gov.

Authors:  Monique L Anderson; Karen Chiswell; Eric D Peterson; Asba Tasneem; James Topping; Robert M Califf
Journal:  N Engl J Med       Date:  2015-03-12       Impact factor: 91.245

3.  CFTR Modulators for the Treatment of Cystic Fibrosis.

Authors:  Rebecca S Pettit; Chris Fellner
Journal:  P T       Date:  2014-07

4.  Reversal of corticosteroid insensitivity by p38 MAPK inhibition in peripheral blood mononuclear cells from COPD.

Authors:  Nadia Khorasani; Josephine Baker; Malcolm Johnson; Kian Fan Chung; Pankaj K Bhavsar
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-02-04

5.  Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team.

Authors:  Jørgen Vestbo; Alvar Agusti; Emiel F M Wouters; Per Bakke; Peter M A Calverley; Bartolome Celli; Harvey Coxson; Courtney Crim; Lisa D Edwards; Nicholas Locantore; David A Lomas; William MacNee; Bruce Miller; Stephen I Rennard; Edwin K Silverman; Julie C Yates; Ruth Tal-Singer
Journal:  Am J Respir Crit Care Med       Date:  2014-05-01       Impact factor: 21.405
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.